Cumberland Pharmaceuticals Inc (CPIX) Stock Price & Analysis
Cumberland Pharmaceuticals Inc (CPIX) fell 5.37% to USD 6.61 as of July 25, 2026 at 06:11 UTC, according to Nexqual real-time market data.
CPIX last closed at USD 6.99; the session ranged USD 6.3–7.05 on volume of 123,332 shares. Market capitalization is $99.04M, with a 52-week range of USD 1.85–8.09 (NMS). Source: Nexqual, July 25, 2026 at 06:11 UTC.
Key Statistics (as of July 25, 2026 at 06:11 UTC)
| Price | USD 6.61 |
|---|---|
| Change | ▼ 5.37% (down) |
| Previous Close | USD 6.99 |
| Open | USD 7.01 |
| Day Range | USD 6.3 – 7.05 |
| 52-Week Range | USD 1.85 – 8.09 |
| Volume | 123,332 shares |
| Market Cap | $99.04M |
| Exchange | NMS |
Technical Analysis (CPIX)
Nexqual's technical model rates CPIX "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 06:11 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.57 (neutral) |
| vs SMA50 | Above (USD 6.11) |
| MACD | 0.34 (positive) |
Analyst Ratings (CPIX)
Wall Street analysts rate CPIX "None", per Nexqual as of July 25, 2026 at 06:11 UTC.
| Consensus Rating | None |
|---|
Earnings (CPIX)
| Next Earnings Date | 2026-08-04 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2021-06-30 | USD -0 vs est -0.07 ▲ beat |
| 2021-03-31 | USD 0.07 vs est -0.07 ▲ beat |
| 2020-12-31 | USD 0.01 vs est -0.01 ▲ beat |
| 2020-09-30 | USD 0.02 vs est -0.07 ▲ beat |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financials & Fundamentals (CPIX)
| Total Revenue | $41.94M |
|---|---|
| Revenue Growth (YoY) | -22.00% |
| Gross Margin | +82.89% |
| Operating Margin | -34.27% |
| Profit Margin | -17.60% |
| ROE | -29.81% |
| Debt / Equity | 47.27 |
| Current Ratio | 0.95 |
| Total Cash | $11.01M |
| Total Debt | $10.07M |
| Free Cash Flow | $4.91M |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financial Health Score (CPIX)
Nexqual rates Cumberland Pharmaceuticals Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:11 UTC.
| Growth | Critical — Revenue -21% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $11M cash vs $10M debt, net cash position |
| Cash Flow | Solid — FCF $5M, 13% margin |
| Efficiency | Critical — ROE -30%, ROA -6.4% |
Ownership (CPIX)
| Insider Ownership | +41.60% |
|---|---|
| Institutional Ownership | +18.65% |
| Shares Outstanding | 14.98M |
| Float | 8.75M |
| Short % of Float | +4.25% |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Leadership (CPIX)
Cumberland Pharmaceuticals Inc is led by A. J. Kazimi (age 67), Founder, Chairman, President & CEO, per Nexqual as of July 25, 2026 at 06:11 UTC.
| Founder, Chairman, President & CEO | A. J. Kazimi (age 67) |
|---|---|
| Vice President Accounting & Finance and CFO | John Michael Hamm C.M.A. (age 69) |
| Vice President of Sales & Marketing | Christopher T. Bitterman (age 60) |
| Vice President of Organizational Development | Todd M. Anthony (age 64) |
| Managing Director of Banking & Investor Relations | Adam S. Mostafa (age 45) |
Major Backers & Investors (CPIX)
Notable institutional backers of Cumberland Pharmaceuticals Inc include Ikarian Capital, LLC, Renaissance Technologies, Perceptive Advisors Llc, according to Nexqual as of July 25, 2026 at 06:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 3.69% |
| Renaissance Technologies | 3.14% |
| Perceptive Advisors Llc | 1.31% |
| Bridgeway Capital Management, LLC | 1.09% |
| Bridgeway Funds, Inc.-Ultra-Small Company Fund | 1.09% |
| Boothbay Fund Management, LLC | 0.85% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Targeted Value Portfolio | 0.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.82% |
| Dimensional Fund Advisors | 2.42% |
| Geode Capital | 0.76% |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
From Cumberland Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center.
- In November 2024, the FDA also approved a supplemental New Drug Application for Acetadote, adding a simplified dosing regimen for the product prescribing information.
- This team has successfully devised regulatory and clinical strategies for our product portfolio, including obtaining FDA approvals for Acetadote and Caldolor brands.
- The court also granted a permanent injunction preventing challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of one of Cumberland's patents in August 2025.
Partnerships
- We also entered into a strategic alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization.
- In August 2020, we entered into an agreement with WinHealth Investment (Singapore) Ltd. creating WHC Biopharmaceuticals, Pte.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| ISPC | iSpecimen Inc. | USD 1.97 | ▼ 12.44% |
| BFRI | Biofrontera Inc. | USD 1.09 | ▲ 0.93% |
| GRTXD | Galera Therapeutics, Inc. | USD 17.5 | ▲ 7.64% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.46 | ▼ 1.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:11 UTC. This page is informational and not investment advice.